Natera, Inc. (NTRA)
| Market Cap | 33.75B |
| Revenue (ttm) | 2.12B |
| Net Income (ttm) | -309.19M |
| Shares Out | 138.01M |
| EPS (ttm) | -2.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,369,753 |
| Open | 242.22 |
| Previous Close | 242.06 |
| Day's Range | 239.00 - 245.59 |
| 52-Week Range | 125.38 - 245.59 |
| Beta | 1.63 |
| Analysts | Strong Buy |
| Price Target | 227.69 (-6.89%) |
| Earnings Date | Nov 6, 2025 |
About NTRA
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissu... [Read more]
Financial Performance
In 2024, Natera's revenue was $1.70 billion, an increase of 56.75% compared to the previous year's $1.08 billion. Losses were -$190.43 million, -56.20% less than in 2023.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $227.69, which is a decrease of -6.89% from the latest price.
News
Natera Acquires Foresight Diagnostics
AUSTIN, Texas & BOULDER, Colo.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular r...
New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Societ...
Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that at least twelve abstracts highlighting Signatera will be shar...
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks
Druckenmiller invests his personal and family's wealth through his fund, the Duquesne Family Office. Druckenmiller is high on biotech stocks, with his top three holdings at the end of the third quarte...
Natera, Inc. (NTRA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Natera, Inc. ( NTRA) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 10:00 AM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Douglas Sch...
Natera, Inc. (NTRA) Presents at Jefferies London Healthcare Conference 2025 Transcript
Natera, Inc. ( NTRA) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Steve Chapman - CEO & Director Mike Brophy - Chief Financial Officer Conference Cal...
Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its employees contributed more than 1,500 volunteer hours dur...
Natera Integrates with Flatiron Health's OncoEMR® Platform
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Flatiron Health, a leading healthtech company dedicated to expanding the possi...
Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript
Natera, Inc. ( NTRA) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Cli...
Natera Reports Third Quarter 2025 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 202...
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand its Fetal Focus test to cover 20 genes, mar...
Natera to Report its Third Quarter Results on November 6, 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September...
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced another successful readout for its ECD program, which is evaluatin...
Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Natera Inc. (NASDAQ: NTRA) breached their fiduciary duties to share...
Natera, Inc. (NTRA) Discusses Findings from ESMO Congress Transcript
Natera, Inc. (NASDAQ:NTRA) Discusses Findings from ESMO Congress October 23, 2025 8:00 AM EDT Company Participants Mike Brophy - Chief Financial Officer Alexey Aleshin - GM of Oncology and ECD & Chie...
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 IMvigor011 clin...
Natera Named to Fast Company's Next Big Things in Tech List
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named to Fast Company's 2025 Next Big Things in T...
Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct. ...
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the ...
Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a milestone in the EXPAND trial with the enrollmen...
Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a peer-reviewed manuscript in the Journal of Cl...
Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology...
Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Natera, Inc. (NASDAQ:NTRA) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 10:30 AM EDT Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Ev...
Can Natera Stock Reach $500?
Let's start with something remarkable. Natera (NASDAQ: NTRA) just marked its 10th anniversary as a public company, and what a journey it has been.
Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript
Natera, Inc. (NASDAQ:NTRA) Baird Global Healthcare Conference 2025 September 9, 2025 8:30 AM EDT Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Conference C...